GLP-1 receptor agonists have been shown to improve lipid profiles, including reductions in total cholesterol and LDL cholesterol, contributing to cardiovascular health
Some insurers demand failed attempts with older, less effective medications first
This is despite an average BMI of 35a data point found within clinician notes in the EMRplacing them squarely within the population clinically eligible for existing injectable therapies
In this regard, GLP-1RAs have shown promising efficacy as to the improvement of hard cardiovascular outcomes with cardiovascular safety
Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, et al
Agenda D1 S1:Opening Remarks and Regulatory Foundations Format: Presentations and a Panel Discussion with Q&A (Virtual and In-Person Attendees) This opening session establishes the regulatory and clinical framework for generic GLP-1 product development